GET DAILY SIGNALSCelularity (CELU): The $1.50 Target and a Potential +97% Upside
Key Takeaways
- The central price target of $1.50 is drawn from public discussion, not an analyst consensus: it matches the conversion price of the senior secured convertible notes and the exercise price of accompanying warrants issued in Celularity's September 2026 recapitalization.
- At a recent price near $0.76, reaching $1.50 would require a gain of roughly 97%, a very large move.
- Only one attributable analyst target is widely reported — a $6.00 price target from WBB Securities (last updated September 2025) — which is far above the current price and was not used to set the central target.
- The strongest supporting factors include a recapitalization of up to $28 million, a manufacturing partnership with MuseCell Innovations, and an estimated $40 million in potential sales value from existing cenplacel-L inventory.
- The biggest risks are persistent operating losses, a lack of product revenue, Nasdaq compliance issues, and potential dilution from convertible notes and warrants.
- For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages covering each.
- Readers can also explore Trending AI Robots to see AI-driven trading strategies across the market.
How the $1.50 Target Came Into View
Celularity Inc. (CELU) is a longevity-focused regenerative and cellular medicine company headquartered in Florham Park, New Jersey, developing placental-derived cell therapies. It is a stock, not an exchange-traded fund.
CELU does not currently have enough fresh, independent analyst price targets to support a meaningful consensus. The only widely cited attributable target is a $6.00 figure from WBB Securities (analyst Steve Brozak), dating to a September 2025 upgrade. That single target is roughly eight times the current share price and reflects a view set when the stock traded materially higher, so it was not used to set the central target. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Instead, the $1.50 objective comes from public discussion and a concrete, company-issued price anchor. In its September 2026 recapitalization, Celularity issued senior secured convertible notes that are initially convertible into Class A common stock at $1.50 per share, with five-year warrants initially exercisable at the same $1.50 price; a second tranche is priced at $2.00 per share. Investors and commentary routinely reference these conversion and exercise prices as the level at which the company's own financing becomes in-the-money. That makes $1.50 a realistic, identifiable milestone rather than an analyst forecast.
Current Market Position and Path Toward the Target
As of early November 2026, CELU traded near $0.76, with a 52-week range of roughly $0.56 to $2.55 and a market capitalization of about $25 million. The stock has negative EPS (earnings per share) of approximately -$1.69 over the trailing twelve months, so it does not have a meaningful P/E (price-to-earnings) ratio.
Reaching $1.50 from about $0.76 would require a gain of roughly 97%, which is a very large move for a company of this size and stage. Any such path would likely depend on converting manufacturing capacity and product inventory into reported revenue, completing the recapitalization, and regaining investor confidence after a sharp decline from levels above $1.30 seen in mid-October 2026.
What Could Support a Move Toward the Target
- Recapitalization: Celularity closed an initial tranche generating over $10 million as part of a plan for up to $28 million, and management targets positive monthly operating cash flow by the end of Q1 2027.
- Manufacturing partnership: Its collaboration with MuseCell Innovations aims to establish U.S. manufacturing of Dezawa MuseCell products; the company has said the expanded relationship could generate over $300 million in purchases over five years.
- Inventory value: Management estimates existing cenplacel-L inventory represents about $40 million in potential sales value, offering a tangible asset base relative to the current market cap.
- Licensing proceeds: A 2026 out-licensing deal with NexGel (NXGL) provided up to $35 million in potential value, including a $15 million upfront payment.
What Could Prevent the Target From Being Reached
- Persistent losses: The company remains unprofitable with no commercial product revenue at scale, and its cash runway depends on continued external financing.
- Dilution: Conversion of the $1.50 notes and exercise of warrants would increase the share count, potentially weighing on the stock price.
- Listing compliance: Celularity faced a Nasdaq notice in August 2026 over delayed 10-Q filings and has a history including a 1-for-10 reverse stock split, underscoring ongoing financial reporting risk.
- Clinical and regulatory uncertainty: Its therapies have not cleared Phase III trials, and deployment of cenplacel-L depends on permissive regulatory pathways that are not guaranteed.
Technical Levels and Market Structure
CELU's 52-week range spans roughly $0.56 to $2.55. The $1.50 level aligns closely with the financing conversion price and sits below the stock's recent October 2026 trading range above $1.30, meaning it could act as both a recovery milestone and a potential resistance zone if approached. Nearer term, the stock has been consolidating below $0.80 after its October decline, with the psychological $1.00 level as an intermediate marker on any path toward $1.50.
Time Horizon and What Investors Should Monitor
The $1.50 anchor is tied to the recapitalization's conversion and warrant exercise terms rather than a standard 12-month research horizon, so no specific analyst timeline applies. Investors should monitor quarterly filings and earnings, progress toward the Q1 2027 positive-cash-flow goal, additional financing closings, revenue recognition from the MuseCell and cenplacel-L efforts, Nasdaq compliance updates, and any analyst revisions. Each of these could shift the market's view of the stock's trajectory.
Final Assessment
Whether Celularity can reach $1.50 depends less on a published analyst consensus — which effectively does not exist — and more on execution of its recapitalization and conversion of its manufacturing and inventory assets into revenue. The roughly 97% move required is very large, and the company must overcome persistent losses, dilution risk, and regulatory uncertainty. The strongest supports are the $1.50 financing anchor, the MuseCell partnership, and the estimated value of its cenplacel-L inventory. Investors should watch cash-flow progress, filings, and financing developments rather than treat $1.50 as a guaranteed outcome.
Using AI Daily Buy/Sell Signals in My Process
Tickeron's AI Daily Buy/Sell Signals have become a regular part of how I review names like CELU. The system scans thousands of stocks and ETFs in real time, flagging shifts in technical behavior and market conditions that might otherwise take longer to spot manually. For a volatile, low-priced stock, these signals help me stay organized and cross-check my own observations without replacing independent judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CELU turns negative, indicating new downward trend
CELU saw its Momentum Indicator move below the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 90 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CELU turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 46 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CELU moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CELU crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CELU entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CELU's RSI Oscillator exited the oversold zone, 32 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELU advanced for three days, in 213 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
CELU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.197) is normal, around the industry mean (3.498). P/E Ratio (-0.228) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.244) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CELU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a blank check company, which focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization
Industry Biotechnology
Advertisement